Measure Type | High Priority Measure? | Collection Type(s) |
---|---|---|
Process | yes | MIPS CQM |
Measure Description
The percentage of patients 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on for at least 75% of their treatment period
Instructions
This measure is to be submitted a minimum of once per performance period for patients with a diagnosis of persistent asthma seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.
NOTE: Patient encounters for this measure conducted via telehealth (e.g., encounters coded with GQ, GT, 95, or POS 02 modifiers) are allowable.
Measure Submission Type:
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.
Denominator
Patients 5-64 years of age with persistent asthma and a visit during the measurement period
DENOMINATOR NOTE: *Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for registry measures.
Denominator Criteria (Eligible Cases):
Patients aged 5-64 years on date of encounter
AND
Diagnosis for persistent asthma (ICD-10-CM): J45.30, J45.31, J45.32, J45.40, J45.41, J45.42, J45.50, J45.51, J45.52
AND
Patient encounter (with or without telehealth) during the performance period (CPT): 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99241*, 99242*, 99243*, 99244*, 99245*, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99381*, 99382*, 99383*, 99384*, 99385*, 99386*, 99387*, 99391*, 99392*, 99393*, 99394*, 99395*, 99396*, 99397*, 99401*, 99402*, 99403*, 99404*, 99411*, 99412*, 99429*, 99455, 99456, 99483, G0402, G0438, G0439, G0463, T1015
AND NOT
DENOMINATOR EXCLUSIONS:
Diagnosis of COPD, Emphysema, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions Due to Fumes/Vapors, Cystic Fibrosis, or Acute Respiratory Failure any time during the patient’s history through the end of the measurement year: E84.0, E84.11, E84.19, E84.8, E84.9, J43.0, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.9, J68.4, J96.00, J96.01, J96.02, J96.20, J96.21, J96.22, J98.2, J98.3
OR
Any patients who had no asthma controller medications dispensed during the measurement year: G9808
OR
Patients who use hospice services any time during the measurement period: G9809
Numerator
The number of patients who achieved a proportion of days (PDC) of at least 75% for their asthma controller medications during the measurement year
Definition:
PDC- The proportion of days covered by at least one asthma controller medication prescription, divided by the number of days in the treatment period. The treatment period is the period of time beginning on the earliest prescription dispensing date for any asthma controller medication during the measurement year through the last day of the measurement year.
Asthma Controller Medications
Description | Prescriptions | Medication Lists | Route |
Antiasthmatic combinations | Dyphylline-guaifenesin | Dyphylline Guaifenesin Medications List | Oral |
Antibody inhibitors | Omalizumab | Omalizumab Medications List | Subcutaneous |
Anti-interleukin-5 | Benralizumab | Benralizumab Medications List | Subcutaneous |
Anti-interleukin-5 | Mepolizumab | Mepolizumab Medications List | Subcutaneous |
Anti-interleukin-5 | Reslizumab | Reslizumab Medications List | Intravenous |
Inhaled steroid combinations | Budesonide-formoterol | Budesonide Formoterol Medications List | Inhalation |
Inhaled steroid combinations | Fluticasone-salmeterol | Fluticasone Salmeterol Medications List | Inhalation |
Inhaled steroid combinations | Fluticasone-vilanterol | Fluticasone Vilanterol Medications List | Inhalation |
Inhaled steroid combinations | Formoterol-mometasone | Formoterol Mometasone Medications List | Inhalation |
Inhaled corticosteroids | Beclomethasone | Beclomethasone Medications List | Inhalation |
Inhaled corticosteroids | Budesonide | Budesonide Medications List | Inhalation |
Inhaled corticosteroids | Ciclesonide | Ciclesonide Medications List | Inhalation |
Inhaled corticosteroids | Flunisolide | Flunisolide Medications List | Inhalation |
Inhaled corticosteroids | Fluticasone | Fluticasone Medications List | Inhalation |
Inhaled corticosteroids | Mometasone | Mometasone Medications List | Inhalation |
Leukotriene modifiers | Montelukast | Montelukast Medications List | Oral |
Leukotriene modifiers | Zafirlukast | Zafirlukast Medications List | Oral |
Leukotriene modifiers | Zileuton | Zileuton Medications List | Oral |
Methylxanthines | Theophylline | Theophylline Medications List | Oral |
Asthma Reliever Medications
Description | Prescriptions | Medication Lists | Route |
Short-acting, inhaled beta-2 agonists | Albuterol | Albuterol Medications List | Inhalation |
Short-acting, inhaled beta-2 agonists | Levalbuterol | Levalbuterol Medications List | Inhalation |
Numerator Options:
Performance Met:
Patient achieved a PDC of at least 75% for their asthma controller medication (G9810)
OR
Performance Not Met:
Patient did not achieve a PDC of at least 75% for their asthma controller medication (G9811)
“
Stay updated with the latest news regarding MACRA and MIPS
The Healthmonix Advisor is a free news source that connects you to the latest in the value-based care industry!